Solving the problem of drug-resistant cancer

To discover ways to prevent or delay resistance to cancer therapies, a new NCI-funded center at OHSU is exploring how acute myeloid leukemia cells evolve and adapt. The first successful targeted...

Zeroing in on drug combos against a formidable form of leukemia

A heat map by Kurtz et al. comparing the sensitivities of leukemia cells to drug combinations. Darker red indicates drug combinations exhibiting higher efficacy than either agent alone. Targeted...

Fighting a formidable leukemia with an expansive clinical trial

The best available treatment for acute myeloid leukemia is a drug combination established more than 30 years ago. And today less than a third of newly diagnosed AML patients survive beyond five...

How a formidable leukemia subverts blood stem cells

New findings open a path for developing desperately needed therapies for the most frequently diagnosed leukemia in adults.   Leukemia paves the way for its deadly advance by manipulating the...

Overcoming the impasse in acute myeloid leukemia research

Nine drug companies and six universities have now joined an unusual collaboration to break the logjam in research on acute myeloid leukemia (AML), a blood cancer lacking effective treatments....

MicroRNA as an early biomarker of leukemia

A preclinical study led by an OHSU Knight Cancer Institute physician may point the way to more effective tests for recurrence of acute myeloid leukemia. Nearly half of patients diagnosed with...